TP53 and neoplasm: As patients with resected tumors after CTx had more frequently proximally located tumors and more advanced tumor stages than patients in the group not treated with CTx, the diverse survival rates may be due to this discrepancy of the CTx and non-CTx patient group and, thus, may also reflect a variation of the prognostic effect of p53 in the different anatomic localizations of the tumor.